JP2023520542A - 治療薬 - Google Patents

治療薬 Download PDF

Info

Publication number
JP2023520542A
JP2023520542A JP2022560369A JP2022560369A JP2023520542A JP 2023520542 A JP2023520542 A JP 2023520542A JP 2022560369 A JP2022560369 A JP 2022560369A JP 2022560369 A JP2022560369 A JP 2022560369A JP 2023520542 A JP2023520542 A JP 2023520542A
Authority
JP
Japan
Prior art keywords
composition
niclosamide
solution
subject
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022560369A
Other languages
English (en)
Japanese (ja)
Inventor
モルテン・ゾマー
ラスムス・トフト－ケーラー
アンネ・カトリーヌ・トフト－ケーラー
マッツ・イェリングソエ
フィリップ・アンドレス
Original Assignee
ユニオン・セラピューティクス・アー／エス
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB2004844.3A external-priority patent/GB202004844D0/en
Priority claimed from GBGB2005340.1A external-priority patent/GB202005340D0/en
Priority claimed from GBGB2010573.0A external-priority patent/GB202010573D0/en
Priority claimed from GBGB2010575.5A external-priority patent/GB202010575D0/en
Priority claimed from GBGB2016289.7A external-priority patent/GB202016289D0/en
Priority claimed from GBGB2016274.9A external-priority patent/GB202016274D0/en
Priority claimed from GBGB2103957.3A external-priority patent/GB202103957D0/en
Application filed by ユニオン・セラピューティクス・アー／エス filed Critical ユニオン・セラピューティクス・アー／エス
Publication of JP2023520542A publication Critical patent/JP2023520542A/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/609—Amides, e.g. salicylamide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
JP2022560369A 2020-04-01 2021-03-26 治療薬 Pending JP2023520542A (ja)

Applications Claiming Priority (15)

Application Number Priority Date Filing Date Title
GB2004844.3 2020-04-01
GBGB2004844.3A GB202004844D0 (en) 2020-04-01 2020-04-01 Treatment
GBGB2005340.1A GB202005340D0 (en) 2020-04-09 2020-04-09 Formulation
GB2005340.1 2020-04-09
GB2010573.0 2020-07-09
GB2010575.5 2020-07-09
GBGB2010573.0A GB202010573D0 (en) 2020-07-09 2020-07-09 Formulation
GBGB2010575.5A GB202010575D0 (en) 2020-07-09 2020-07-09 Treatment
GB2016274.9 2020-10-14
GBGB2016289.7A GB202016289D0 (en) 2020-10-14 2020-10-14 Treatment
GBGB2016274.9A GB202016274D0 (en) 2020-10-14 2020-10-14 Formulation
GB2016289.7 2020-10-14
GB2103957.3 2021-03-22
GBGB2103957.3A GB202103957D0 (en) 2021-03-22 2021-03-22 Treatment
PCT/EP2021/058046 WO2021198115A1 (en) 2020-04-01 2021-03-26 Treatment

Publications (1)

Publication Number Publication Date
JP2023520542A true JP2023520542A (ja) 2023-05-17

Family

ID=75302583

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022560369A Pending JP2023520542A (ja) 2020-04-01 2021-03-26 治療薬

Country Status (11)

Country Link
US (1) US20230147683A1 (ko)
EP (1) EP4125804A1 (ko)
JP (1) JP2023520542A (ko)
KR (1) KR20230020952A (ko)
CN (1) CN115701984A (ko)
AU (1) AU2021248603A1 (ko)
BR (1) BR112022019519A2 (ko)
CA (1) CA3173163A1 (ko)
IL (1) IL296898A (ko)
MX (1) MX2022012360A (ko)
WO (1) WO2021198115A1 (ko)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022169373A1 (en) * 2021-02-04 2022-08-11 Alan Moana Alexander Niclosamide compositions having improved bioavailability
GB202102488D0 (en) * 2021-02-22 2021-04-07 Union Therapeutics As Treatment
CN113908121B (zh) * 2021-10-13 2023-03-28 中国农业科学院上海兽医研究所(中国动物卫生与流行病学中心上海分中心) 一种氯硝柳胺注射液及其制备和应用
US20230301903A1 (en) * 2022-03-25 2023-09-28 Neurelis, Inc. Intranasal olanzapine formulations and methods of their use
KR20240032430A (ko) * 2022-09-02 2024-03-12 주식회사 스카이테라퓨틱스 니클로사미드의 신규 염, 이의 분자회합체 및 이를 포함하는 약학 조성물

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19953317C1 (de) 1999-11-05 2001-02-01 Pari Gmbh Inhalationsvernebler
DE10004465A1 (de) 2000-02-02 2001-08-16 Pari Gmbh Inhalationsvernebler
DE10022795B4 (de) 2000-05-10 2005-04-14 Pari GmbH Spezialisten für effektive Inhalation Atemgesteuertes Inhalationstherapiegerät
DE10040528A1 (de) 2000-08-18 2002-02-28 Pari Gmbh Inhalationsvorrichtung und Verfahren zur Erzeugung eines Partikelnebels für Inhalationszwecke
DE10102846B4 (de) 2001-01-23 2012-04-12 Pari Pharma Gmbh Aerosolgenerator
EP1304131B1 (de) 2001-10-18 2005-06-29 PARI GmbH Spezialisten für effektive Inhalation Inhalationstherapievorrichtung
EP1304130B1 (de) 2001-10-18 2004-06-23 PARI GmbH Spezialisten für effektive Inhalation Inhalationstherapievorrichtung
DE10229889A1 (de) 2002-07-03 2004-01-29 Pari GmbH Spezialisten für effektive Inhalation Inhalationstherapievorrichtung
EP1386672B1 (en) 2002-08-02 2010-04-07 PARI Pharma GmbH Fluid droplet production apparatus
DE10239321B3 (de) 2002-08-27 2004-04-08 Pari GmbH Spezialisten für effektive Inhalation Aerosoltherapievorrichtung
DE10243371B4 (de) 2002-09-18 2006-06-14 Pari GmbH Spezialisten für effektive Inhalation Aeorosoltherapiegerät
DE10250625A1 (de) 2002-10-30 2004-05-19 Pari GmbH Spezialisten für effektive Inhalation Inhalationstherapievorrichtung
DE10251864B3 (de) 2002-11-07 2004-06-24 Pari GmbH Spezialisten für effektive Inhalation Inhalationstherapievorrichtung
DE10251865B3 (de) 2002-11-07 2004-05-13 Pari GmbH Spezialisten für effektive Inhalation Inhalationstherapievorrichtung
DE10257381B4 (de) 2002-12-09 2006-09-14 Pari GmbH Spezialisten für effektive Inhalation Inhalationstherapievorrichtung
DE10320143A1 (de) 2003-05-06 2004-12-16 Pari GmbH Spezialisten für effektive Inhalation Vernebleranschlussvorrichtung für Beatmungsgeräte oder dergleichen
TWI343810B (en) * 2003-05-28 2011-06-21 Nat Health Research Institutes A pharmaceutical composition for inhibiting coronavirus
DE10345950A1 (de) 2003-10-02 2005-05-19 Pari GmbH Spezialisten für effektive Inhalation Inhalationstherapievorrichtung mit Ventil
DE10347994A1 (de) 2003-10-15 2005-06-16 Pari GmbH Spezialisten für effektive Inhalation Wässrige Aerosol-Zubereitung
DE10348237A1 (de) 2003-10-16 2005-05-19 Pari GmbH Spezialisten für effektive Inhalation Inhalationstherapievorrichtung mit einem Düsenvernebler
DE102005006374B3 (de) 2005-02-11 2006-07-20 Pari GmbH Spezialisten für effektive Inhalation Aerosolerzeugungsvorrichtung und Inhalationstherapiegerät mit einer derartigen Vorrichtung
DE102005006372B4 (de) 2005-02-11 2007-11-29 Pari GmbH Spezialisten für effektive Inhalation Inhalationstherapievorrichtung und Verfahren zu deren Betrieb
EP1712220A1 (en) 2005-04-15 2006-10-18 PARI GmbH Spezialisten für effektive Inhalation Pharmaceutical aerosol composition
DE102005024779B4 (de) 2005-05-31 2008-02-21 Pari GmbH Spezialisten für effektive Inhalation Atemzuggesteuerte Inhalationstherapievorrichtung
DE102005038619A1 (de) 2005-08-16 2007-02-22 Pari GmbH Spezialisten für effektive Inhalation Inhalationstherapievorrichtung mit einer Ampulle für die Bevorratung eines zu vernebelnden Medikaments
CA2641872A1 (en) 2006-02-09 2007-08-16 Kamada Ltd. Alpha-i antitrypsin for treating exacerbation episodes of pulmonary diseases
DE102006017002B3 (de) 2006-04-11 2007-01-11 Pari GmbH Spezialisten für effektive Inhalation Inhalationstherapievorrichtung mit mehrfachen Düsen
DE102007012804A1 (de) 2007-03-16 2008-09-25 Pari Pharma Gmbh Aerosolgenerator
DE102008022987A1 (de) 2008-05-09 2009-11-12 Pari Pharma Gmbh Vernebler für Beatmungsmaschinen und Beatmungsmaschine mit einem solchen Vernebler
DE102008054431B3 (de) 2008-12-09 2010-06-17 Pari Pharma Gmbh Aerosoltherapievorrichtung
DE102009001037B4 (de) 2009-02-20 2013-02-21 Pari Pharma Gmbh Inhalationstherapievorrichtung
ES2628077T3 (es) 2009-02-27 2017-08-01 Pari GmbH Spezialisten für effektive Inhalation Dispositivo de inhalación de aerosol
DE102009026636B4 (de) 2009-06-02 2011-04-14 Pari Pharma Gmbh Verfahren zum Verschweißen einer Membran mit einem Träger bei der Herstellung eines Membranverneblers
EP2380618A1 (en) 2010-04-26 2011-10-26 PARI Pharma GmbH Operating method for an aerosol delivery device and aerosol delivery device
EP2457609A1 (en) 2010-11-24 2012-05-30 PARI Pharma GmbH Aerosol generator
EP3777938B1 (en) 2011-06-08 2023-08-02 PARI Pharma GmbH Aerosol generator
DE102011079810B4 (de) 2011-07-26 2013-04-04 Pari Pharma Gmbh Einwegampulle zum Einsetzen in einen Aerosolerzeuger
EP2708219A1 (en) 2012-09-12 2014-03-19 PARI Pharma GmbH Opening element for opening an ampoule in an aerosol generation device and aerosol generation device comprising the opening element
EP2735328A1 (en) 2012-11-27 2014-05-28 PARI Pharma GmbH Fluid reservoir for an aerosol generation device, combination of fluid reservoir and primary fluid package, and aerosol generation device for use with the fluid reservoir
EP2883564A1 (en) 2013-12-16 2015-06-17 PARI Pharma GmbH Aerosol delivery device and method of operating the aerosol delivery device
EP2910268A1 (en) 2014-02-25 2015-08-26 PARI Pharma GmbH Inhalator and inhalator set
US10583221B2 (en) * 2014-05-12 2020-03-10 Gholam A. Peyman Method of corneal transplantation or corneal inlay implantation with cross-linking
EP2957349A1 (en) 2014-06-20 2015-12-23 PARI Pharma GmbH Aerosol generator and aerosol delivery device comprising the aerosol generator
DE102014215064A1 (de) 2014-07-31 2016-02-04 Pari GmbH Spezialisten für effektive Inhalation Vernebler
EP2987520A1 (en) 2014-08-18 2016-02-24 PARI Pharma GmbH Fluid reservoir for an aerosol generator and aerosol generator comprising the fluid reservoir
JP2017529393A (ja) 2014-09-12 2017-10-05 アンティバイオティクス エーピーエスＡｎｔｉｂｉｏｔｘ Ａｐｓ ハロゲン化サリチルアニリドの抗菌用途
EP3037120A1 (en) 2014-12-23 2016-06-29 PARI Pharma GmbH Aerosol delivery device and operating method for the aerosol delivery device
ES2654803T3 (es) 2015-08-03 2018-02-15 Pari Pharma Gmbh Método de fabricación de un cabezal vibratorio para un generador de aerosol y cabezal vibratorio para un generador de aerosol
GB201604484D0 (en) 2016-03-16 2016-04-27 Antibiotx Aps And Københavns Uni University Of Copenhagen Topical antibacterial compositions
WO2017223491A1 (en) * 2016-06-23 2017-12-28 Health Research, Inc. Pharmaceutical compositions with antiflaviviral activity
EP3375473A1 (en) 2017-03-17 2018-09-19 PARI Pharma GmbH Control device for aerosol nebulizer system
CA3057284A1 (en) * 2017-03-21 2018-09-27 Novalead Pharma Inc. Therapeutic agent for phosphodiesterase inhibition and its related disorders
GB201713653D0 (en) * 2017-08-24 2017-10-11 Antibiotx As Dosage regimen
WO2019115771A1 (en) 2017-12-15 2019-06-20 Pari Pharma Gmbh Nebuliser system, holding system, combination comprising nebuliser system and holding system, and aerosol administration method
EP3556475A1 (en) 2018-04-20 2019-10-23 PARI GmbH Spezialisten für effektive Inhalation Controller for an aerosol generator
CN110833623A (zh) * 2019-12-20 2020-02-25 沈阳药科大学 氯硝柳胺乙醇胺盐-羟丙基-β-环糊精包合物及其制备

Also Published As

Publication number Publication date
CN115701984A (zh) 2023-02-14
WO2021198115A1 (en) 2021-10-07
EP4125804A1 (en) 2023-02-08
BR112022019519A2 (pt) 2022-11-16
IL296898A (en) 2022-12-01
MX2022012360A (es) 2022-10-21
US20230147683A1 (en) 2023-05-11
CA3173163A1 (en) 2021-10-07
AU2021248603A1 (en) 2022-11-10
KR20230020952A (ko) 2023-02-13

Similar Documents

Publication Publication Date Title
US11324708B1 (en) Niclosamide formulations for treating disease
US20230147683A1 (en) Treatment
US20230190685A1 (en) Formulation
US11975005B2 (en) Treatment of respiratory diseases
WO2021229514A1 (en) Pharmaceutical ivermectin compositions
JP2023526547A (ja) 気道粘膜におけるウイルス複製を低下させるための特定の薬物のシステム、方法、及び使用
US20220000808A1 (en) Cysteamine for the Treatment, Mitigation and Prevention of Coronaviral, e.g., SARS-CoV-2, Infections
US11160814B1 (en) Methods of treatment for disease from coronavirus exposure
JP2023520929A (ja) コロナウイルス感染症の処置のための方法
WO2022175689A1 (en) Treatment
US20220025019A1 (en) Methods and compositions for preventing or treating acute exacerbations with polyclonal immunoglobulin
US20220054509A1 (en) Methods of treatment for disease from coronavirus exposure
US20220304959A1 (en) Treatment of long haulers syndrome with niclosamide
CN116744934A (zh) 用于治疗病毒性呼吸疾病的吸入性他汀类药物
CN116472054A (zh) 用于改善SARS-CoV-2感染患者的预后的吸入型干扰素-β
WO2005056009A1 (ja) 肺疾患治療剤